Treatment of tinnitus using glutamate receptor agonists
AssigneeNortheast Ohio Medical University
InventorAlexander V. Galazyuk
Life of this patent
Estimating the term…
Abstract
A method of treating tinnitus in a subject is described that includes administering a therapeutically effective amount of a group II metabotropic glutamate receptor (mGluR) agonist to the subject. A method of screening a subject having tinnitus for treatment with a group II mGluR agonist that includes testing the use of residual inhibition to suppress tinnitus in the subject, wherein suppression of tinnitus by residual inhibition indicates that a group II mGluR agonist would be effective for treating tinnitus in the subject, is also described.
Claims13
A method of temporarily suppressing tinnitus in a subject, comprising administering a therapeutically effective amount of a group II metabotropic glutamate receptor (mGluR) agonist to the subject.
A method of screening a subject having tinnitus for temporary suppression of tinnitus with a group II metabotropic glutamate receptor (mGluR) agonist, comprising testing the use of residual inhibition to suppress tinnitus in the subject, wherein suppression of tinnitus by residual inhibition indicates that a group II mGluR agonist would be effective for temporarily suppressing tinnitus in the subject, further comprising administering a therapeutically effective amount of a group II mGluR agonist to a subject in which tinnitus is suppressed by residual inhibition.
Dependencies are inferred from the claim text.